6/24/2016 | CV | Pfizer closes Anacor acquisition, triggers convertibles’ make-whole
|
5/18/2016 | CV | Market Commentary: inContact surges on swap after takeout news; Tesla gains ahead of secondary offering news
|
5/17/2016 | PP | Market Commentary: Allegheny Technologies launches new deal; Pandora eyed after activist investors urge sales
|
5/17/2016 | CV | Market Commentary: Allegheny Technologies launches new deal; Pandora eyed after activist investors urge sales
|
5/16/2016 | PP | Market Commentary: Anacor bonds contract on swap on takeout news; Teligent adds; Wright Medical extends gains
|
5/16/2016 | CV | Market Commentary: Anacor bonds contract on swap on takeout news; Teligent adds; Wright Medical extends gains
|
5/16/2016 | CV | Market Commentary: Morning Commentary: Anacor bonds contract on swap after takeout news; SandRidge bankruptcy eyed
|
5/12/2016 | CV | Market Commentary: Qihoo convertibles slip back; YY trades; health care mostly lower; Jazz, Horizon down
|
4/12/2016 | PP | Market Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake extends gains
|
4/12/2016 | CV | Market Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake extends gains
|
4/12/2016 | CV | Market Commentary: Morning Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake gains
|
4/7/2016 | CV | Market Commentary: Healthcare flies higher as out-of-favor sector enjoys resurgence; DepoMed, BioMarin improve
|
4/6/2016 | PP | Market Commentary: Anacor rises amid speculation it’s a target; other health care names better to buy
|
4/6/2016 | CV | Market Commentary: Anacor rises amid speculation it’s a target; other health care names better to buy
|
4/6/2016 | CV | Anacor greenshoe exercised, lifts 2% convertibles to $287.5 million
|
4/6/2016 | CV | Market Commentary: Morning Commentary: Anacor rises amid speculation it’s a target; health care better to buy
|
4/5/2016 | CV | Market Commentary: Convertibles steady despite slip in stocks; Gilead active ahead of maturity; Tesla firmer
|
4/4/2016 | PP | Market Commentary: SunEdison convertible bonds languish below 4; Tesla up on new sedan orders; Anacor gains
|
4/4/2016 | CV | Market Commentary: SunEdison convertible bonds languish below 4; Tesla up on new sedan orders; Anacor gains
|
4/4/2016 | CV | Market Commentary: Morning Commentary: Tesla trading on new sedan orders; Anacor extends gains; Lam Research trading
|
4/1/2016 | PP | Market Commentary: Anacor up slightly on outright basis; new Gran Tierra adds; Rovi expands dollar neutral
|
4/1/2016 | CV | Market Commentary: Anacor up slightly on outright basis; new Gran Tierra adds; Rovi expands dollar neutral
|
4/1/2016 | CV | Market Commentary: Morning Commentary: New Anacor up slightly on an outright basis; new Gran Tierra adds
|
3/31/2016 | CV | New Issue: Anacor prices $250 million seven-year convertibles to yield 2%, up 32.5%
|
3/31/2016 | PP | Market Commentary: Planned Anacor convertible looks about 2 points cheap; Gran Tierra, Medallion also on deck
|
3/31/2016 | CV | Market Commentary: Planned Anacor convertible looks about 2 points cheap; Gran Tierra, Medallion also on deck
|
3/31/2016 | CV | Market Commentary: Morning Commentary: Convertibles market eyes new deals from Anacor, Gran Tierra, Medallion
|
3/30/2016 | PP | Market Commentary: SunEdison convertibles drop; Verint Systems lower after earnings; Anacor, Medallion on tap
|
3/30/2016 | CV | Market Commentary: SunEdison convertibles drop; Verint Systems lower after earnings; Anacor, Medallion on tap
|
3/30/2016 | CV | Anacor plans to price $250 million seven-year convertibles to yield 1.75%-2.25%, up 30%-35%
|
10/20/2014 | PP | Market Commentary: Convertibles market players watching for next trend; Ares Capital, American Realty better
|
10/20/2014 | CV | Market Commentary: Convertibles market players watching for next trend; Ares Capital, American Realty better
|
10/16/2014 | CV | Anacor greenshoe exercise brings 2% convertibles to $82.5 million
|
10/10/2014 | PP | Market Commentary: Tech sags after Microchip sales warning; energy names weaken further; new Anacor quiet
|
10/10/2014 | CV | Market Commentary: Tech sags after Microchip sales warning; energy names weaken further; new Anacor quiet
|
10/10/2014 | CV | Market Commentary: Morning Commentary: Anacor quiet after pricing through rich end; Microchip drops on sales warning
|
10/9/2014 | PP | Anacor to place $8 million seven-year 2% convertibles with Venrock
|
10/9/2014 | CV | New Issue: Anacor prices $75 million seven-year 2% convertibles, up 35%
|
10/9/2014 | CV | Market Commentary: Convertibles sink; Cobalt, energy names slide; Alcoa preferreds hold in light volume
|
10/8/2014 | CV | Market Commentary: Dynegy finishes ‘in line’; Starwood Waypoint expands; E&P names suffer, Energy XXI drops
|
10/8/2014 | CVPP | Anacor Pharmaceuticals to price $70 million seven-year convertibles to yield 2.5%-3%, up 30%-35%
|
6/12/2013 | PP | Anacor settles $30 million of $45 million variable-rate loan financing
|
5/1/2013 | PP | Anacor greenshoe exercised for $23 million public offering of stock
|
4/26/2013 | PP | Anacor prices $20 million public offering of common stock at $6.39
|
4/25/2013 | PP | Anacor Pharmaceuticals plans to price public sale of common stock
|
4/8/2013 | PP | Anacor Pharmaceuticals concludes $5 million private placement of stock
|
1/18/2013 | PP | Anacor to sell $25 million via stock equity distribution agreement
|
1/18/2013 | PP | Anacor to sell $25 million via stock equity distribution agreement
|
12/14/2012 | CVHYPF | Anacor files $75 million shelf covering stock, preferreds and debt
|
10/18/2012 | PP | Anacor Pharmaceuticals prices $24 million public stock sale at $6.00
|
10/17/2012 | PP | Anacor Pharmaceuticals reports plans to price public sale of shares
|
2/8/2012 | PP | Anacor Pharmaceuticals plans $21.45 million public offering of shares
|
12/30/2011 | CVHYPF | Anacor files $50 million shelf covering stock, preferreds and debt
|
3/21/2011 | PP | Anacor Pharmaceuticals arranges $30 million four-year loan agreement
|
11/30/2010 | PP | Anacor Pharmaceuticals wraps $10 million private placement of shares
|